Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Lynn who wrote (11597)	6/12/2018 1:41:00 PM
From: scaram(o)uche	Read Replies (3) \| Respond to of 12215

Lynn, be sure to review comments at twitter. Comments include their not having hit statistical significance on an endpoint that they claimed having hit, and a need for near-term funding... a secondary. I don't know the issue or management, just trying to help you as a relative newbie. One of the best ways to find biotechs is to find them BEFORE news hits. One way to do that is to follow individuals like Andy Biotech at twitter or a thread like this, here at S.I...... Subject 59918 >> I'm in no hurry to jump on it << Good to hear! One point not being discussed at twitter is that the molecule is old, and I believe that prolonged patent protection is dependent on a "use" patent. No problem there, unless any future, unforeseen challenge has merit. Looks like Dew and Miljenko have been up to eyeballs, so I'll bow out.

To: Lynn who wrote (11597)	6/12/2018 2:04:30 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 12215

<I am not asking you as an easy way out of doing research, rather asking for an opinion since you would not have picked something for trading without some insight into the company.> As a NASH company I have them with eye open. After BVF tinvested $6M for 1 m shares, I expand my DD on compound and took trading position. I would like to have all data without any censoring, and with possibility to compare/evaluate further. I guess, presentation at conference or per-view article may do it. At this point, reported data do generate optimism that compound (most likely in combination, compound is SAFE on its own) has some sort of potential for NASH. Is this enough to take position on 250-300 M EV bios with NASH candidate "clearing" P2 stage?? That is you to decided. I am out, simple because I got 350% return very quickly. In my pass days when I come here in US and started working at Chemica, I would need full year to mach my gain on GLMD. I was LUCKY!